Filtered By:
Specialty: Allergy & Immunology
Vaccination: Hepatitis Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 254 results found since Jan 2013.
Vaccination coverage survey of children aged 1-3 years in Beijing, China, 2005-2021
CONCLUSION: The coverage level and service quality of routine immunization in Beijing were relatively high. However, as influenced by COVID-19 epidemics, both on-time and in-time vaccination rates decreased significantly, except for BCG and HepB. Under the background of COVID-19 pandemic, the keys to maintain high level of vaccination coverage include flexible immunization service time to ensure the guardians bringing their children for vaccination timely, and more attention from providers to the doses after children's first birthday.PMID:37709591 | DOI:10.1016/j.vaccine.2023.08.015
Source: Vaccine - September 14, 2023 Category: Allergy & Immunology Authors: Wen-Yan Ji Dong-Lei Liu Rui Yu Liang Miao Qian-Li Yuan Luo-Dan Suo Jian-Ping Yu Source Type: research
Eliminating hepatitis B vaccination disparities for West African immigrants
Vaccine. 2023 Sep 3:S0264-410X(23)01012-5. doi: 10.1016/j.vaccine.2023.08.058. Online ahead of print.ABSTRACTBACKGROUND: Hepatitis B virus (HBV) infection is endemic in West Africa. There has been a significant increase in the Bronx West African (WA) community. To achieve HBV elimination, vaccination of non-immune individuals is important. Unfortunately, vaccine uptake in immigrant populations is at this time very limited.METHODS: An educational program was conducted by medical providers of WA origin in collaboration with local faith-based organizations, after which free HBV screening was offered. Non-immune individuals we...
Source: Vaccine - September 5, 2023 Category: Allergy & Immunology Authors: Jessie A Birnbaum Daniel Guttman Mugdha Parulekar Fatima Omarufilo Emmanuel U Emeasoba Julie Nguyen Oluwadara Tokunboh Jared Coe Matthew J Akiyama Samuel H Sigal Source Type: research
Immunogenicity and safety of Havisure < sup > TM < /sup > vaccine developed by Human Biologicals Institute in healthy subjects of 12 months to 49 years of age: A phase II/III, randomized, single blind, non-inferiority study
CONCLUSION: The study results indicate that the Havisure™ vaccine is immunogenic and safe when administered to healthy subjects of 12 months to 49 years of age, and is non-inferior to Havrix® Vaccine.PMID:37661535 | DOI:10.1016/j.vaccine.2023.08.084
Source: Vaccine - September 4, 2023 Category: Allergy & Immunology Authors: Sai Krishna Susarla Madhu Gupta Kheya Ghosh Uttam Sonali Palkar Ashish Ramachandra Dhongade K Siva Ram Prasad Vasudev Rajapantula M D Ravi N Pradeep M Satish B C Rajashakar G Sandhya L Rajendra Devi Prasad Sahoo Anand Kumar Kanakasapapathy Source Type: research
Impact of frequency and duration of freeze-dried inactivated tissue culture hepatitis A vaccine (Aimmugen ®) vaccination on antibody titers; a japanese cross-sectional study
CONCLUSIONS: Three doses of Aimmugen® are efficacious, but four or more doses induce more robust and sustained antibody production. Additionally, four or more doses may be effective when there is a need to ensure long-term immunity or risk of prolonged exposure.PMID:37620202 | DOI:10.1016/j.vaccine.2023.08.030
Source: Vaccine - August 24, 2023 Category: Allergy & Immunology Authors: Yohei Maki Naoki Edo Makoto Mizuguchi Mikihito Ikeda Masato Kitano Etsuko Kitagami Morichika Osa Shotaro Yamamoto Takunori Ogawa Takahiro Nakamura Akihiko Kawana Yoshifumi Kimizuka Source Type: research
Mapping the timeliness of routine childhood vaccination in The Gambia: A spatial modelling study
CONCLUSIONS: Our approach provides decision-makers with a valuable tool to better understand local patterns of untimely childhood vaccination and identify districts where strengthening vaccine delivery systems could have the greatest impact.PMID:37563051 | DOI:10.1016/j.vaccine.2023.08.004
Source: Vaccine - August 10, 2023 Category: Allergy & Immunology Authors: Oghenebrume Wariri Chigozie Edson Utazi Uduak Okomo C Jessica E Metcalf Malick Sogur Sidat Fofana Kris A Murray Chris Grundy Beate Kampmann Source Type: research
Modeling the impact of vaccination for the immunization Agenda 2030: Deaths averted due to vaccination against 14 pathogens in 194 countries from 2021 to 2030
Vaccine. 2023 Aug 1:S0264-410X(23)00854-X. doi: 10.1016/j.vaccine.2023.07.033. Online ahead of print.ABSTRACTBACKGROUND: The Immunization Agenda 2030 (IA2030) Impact Goal 1.1. aims to reduce the number of future deaths averted through immunization in the next decade. To estimate the potential impact of the aspirational coverage targets for IA2030, we developed an analytical framework and estimated the number of deaths averted due to an ambitious vaccination coverage scenario from 2021 to 2030 in 194 countries.METHOD: A demographic model was used to determine annual age-specific mortality estimates associated with vaccine c...
Source: Vaccine - August 3, 2023 Category: Allergy & Immunology Authors: Austin Carter William Msemburi So Yoon Sim Katy A M Gaythorpe Philipp Lambach Ann Lindstrand Raymond Hutubessy Source Type: research
Timeliness in the uptake of hepatitis B birth dose among Indian children under age five: A population-based study
CONCLUSION: Results indicated a need for targeted interventions to improve the coverage and timeliness in the uptake of this critical vaccine dose in the country. These interventions could include strategies such as strengthening the healthcare system, improving awareness among parents and healthcare providers, addressing logistical challenges in vaccine delivery, and promoting community engagement and education on importance of timely vaccination.PMID:37468388 | DOI:10.1016/j.vaccine.2023.07.015
Source: Vaccine - July 19, 2023 Category: Allergy & Immunology Authors: Sumit Kumar Das Junaid Khan Source Type: research
Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice
Vaccine. 2023 Jun 28:S0264-410X(23)00783-1. doi: 10.1016/j.vaccine.2023.06.080. Online ahead of print.ABSTRACTAs the COVID-19 pandemic transitions into endemicity, seasonal boosters are a plausible reality across the globe. We hypothesize that intranasal vaccines can provide better protection against asymptomatic infections and more transmissible variants of SARS-CoV-2. To formulate a protective intranasal vaccine, we utilized a VLP-based platform. Hepatitis B surface antigen-based virus like particles (VLP) linked with receptor binding domain (RBD) antigen were paired with the TLR4-based agonist adjuvant, BECC 470. K18-hA...
Source: Vaccine - July 5, 2023 Category: Allergy & Immunology Authors: Katherine S Lee Nathaniel A Rader Olivia A Miller-Stump Melissa Cooper Ting Y Wong Md Shahrier Amin Mariette Barbier Justin R Bevere Robert K Ernst F Heath Damron Source Type: research
